---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-019844"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:13:32.799643+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Qualigen granted patents for QN-302 covering 25 countries through 2040

## Summary
- Patents for QN-302 granted in over 20 European countries plus India, China, and Russia.
- Patent titled 'Substituted Naphthalene Diimides and Their Use' covers product and manufacturing methods.
- Expiration extends to 2040; drug targets pancreatic and gastrointestinal cancers.
- Qualigen licensed QN-302 from University College of London (Prof. Stephen Neidle).
- CEO states patent coverage strengthens position as drug development company.

## SEC filing metadata
- accession: 0001641172-25-019844
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000164117225019844/0001641172-25-019844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000164117225019844/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-019844
- JSON: https://secwatch.observer/filing/0001641172-25-019844.json
- Plain text: https://secwatch.observer/filing/0001641172-25-019844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.